TIDMAREC

RNS Number : 1835Q

Arecor Therapeutics PLC

25 October 2021

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

Exercise of options, PDMR dealing and Total Voting Rights

Cambridge, UK, 25 October 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives , announces that it has issued and allotted 151,492 new Ordinary Shares of 1 pence each in the share capital of the Company following an exercise of options on 25 October 2021 at an exercise price of 1 pence per Ordinary Share. The options exercised were part of the rollover of share options previously granted under the historic Arecor Limited EMI Share Option Plan 2018 ("Option Rollover"). Details of the Option Rollover are set out in the Company's Admission Document.

Included in the exercise of options were options over 123,336 ordinary shares held by Directors/PDMRs of the Company as detailed in the table below:

 
 Director/ PDMR       Position               Existing            Number of          Resultant          Options 
                                             interest in         Options over       interest in        remaining after 
                                             Ordinary Shares     Ordinary           Ordinary           exercise 
                                                                 Shares             Shares 
                                                                 exercised 
 David Gerring        VP, Development        142,956             8,336              151,292            83,334 
                     -------------------  ------------------  -----------------  -----------------  ------------------ 
                      Chief Executive 
 Sarah Howell          Officer               788,742             51,664             840,406            360,666 
                     -------------------  ------------------  -----------------  -----------------  ------------------ 
                      Chief Scientific 
 Jan Jezek             Officer               396,138             8,336              404,474            163,334 
                     -------------------  ------------------  -----------------  -----------------  ------------------ 
                      VP, Clinical & 
                       Regulatory 
 Fiona Lawrence        Affairs               66,168              4,166              70,334             81,666 
                     -------------------  ------------------  -----------------  -----------------  ------------------ 
                      Chief Financial 
 Susan Lowther         Officer               110,681             25,834             136,515            322,000 
                     -------------------  ------------------  -----------------  -----------------  ------------------ 
 James                VP, Business 
  MacDonald-Clink      Development           -                   25,000             25,000             105,000 
                     -------------------  ------------------  -----------------  -----------------  ------------------ 
 

Admission

Following the above transactions, application has been made for the 151,492 new Ordinary Shares to be admitted to trading on AIM ("Admission") and dealings are expected to commence on, or around, 29 October 2021. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.

The total number of Ordinary Shares in issue following Admission will be 27,835,024. Accordingly, the figure of 27,835,024 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

 
 Arecor Therapeutics plc                   www.arecor.com 
 Dr Sarah Howell, Chief Executive          Tel: +44 (0) 1223 426060 
  Officer                                   Email: info@arecor.com 
 
 Susan Lowther, Chief Financial Officer    Tel: +44 (0) 1223 426060 
                                            Email: info@arecor.com 
 
 Mo Noonan, Communications                 Tel: +44 (0) 7876 444977 
                                            Email: mo.noonan@arecor.com 
 
 
   Panmure Gordon (UK) Limited               Tel: +44 (0) 20 7886 2500 
   (NOMAD and Broker) 
   Freddy Crossley, Emma Earl (Corporate 
   Finance) 
   Rupert Dearden (Corporate Broking) 
 
 
   Consilium Strategic Communications 
 Chris Gardner, David Daley, Angela        Tel: +44 (0) 20 3709 5700 
  Gray                                      Email: arecor@consilium-comms.com 
 

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM), we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat (TM) platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
      Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name:                                   a) David Gerring 
                                               b) Sarah Howell 
                                               c) Jan Jezek 
                                               d) Fiona Lawrence 
                                               e) Susan Lowther 
                                               f) James MacDonald-Clink 
     ---------------------------------  ----------------------------------------- 
 2.   Reason for the notification 
     ---------------------------------------------------------------------------- 
 a)   Position/status:                              a) VP, Development 
                                                     b) Chief Executive Officer 
                                                     c) Chief Scientific Officer 
                                                     d) VP, Clinical & Regulatory 
                                                     Affairs 
                                                     e) Chief Financial Officer 
                                                     f) VP, Business Development 
     ---------------------------------  ----------------------------------------- 
 b)   Initial notification/Amendment:    Initial notification 
     ---------------------------------  ----------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ---------------------------------------------------------------------------- 
 a)   Name:                              Arecor Therapeutics PLC 
     ---------------------------------  ----------------------------------------- 
 b)   LEI:                               98450093D12I3A8DDD58 
     ---------------------------------  ----------------------------------------- 
 4.   Details of the transaction(s): section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv) each place where transactions have been 
       conducted 
     ---------------------------------------------------------------------------- 
 a)   Description of the financial       Ordinary shares of 1 pence 
       instrument, type of instrument:    each 
       Identification code:               GB00BMWLM973 
     ---------------------------------  ----------------------------------------- 
 b)   Nature of the transaction:         Exercise of options over ordinary 
                                          shares 
     ---------------------------------  ----------------------------------------- 
 c)   Price(s) and volume(s):              Price(s)     Volume(s) 
                                            a) GBP0.01   a) 8,336 
                                                        ---------- 
                                            b) GBP0.01   b) 51,664 
                                                        ---------- 
                                            c) GBP0.01   c) 8,336 
                                                        ---------- 
                                            d) GBP0.01   d) 4,166 
                                                        ---------- 
                                            e) GBP0.01   e) 25,834 
                                                        ---------- 
                                            f) GBP0.01   f) 25,000 
                                                        ---------- 
     ---------------------------------  ----------------------------------------- 
 d)   Aggregated information: 
        *    Aggregated volume:            123,336 
                                           GBP0.01 
 
        *    Price: 
     ---------------------------------  ----------------------------------------- 
 e)   Date of the transaction:           25 October 2021 
     ---------------------------------  ----------------------------------------- 
 f)   Place of the transaction:          London Stock Exchange, AIM 
                                          Market (XLON) 
     ---------------------------------  ----------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBUBDGXDDDGBU

(END) Dow Jones Newswires

October 25, 2021 11:25 ET (15:25 GMT)

Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Arecor Therapeutics Charts.
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Arecor Therapeutics Charts.